1. Poliovirus serological assay after the cVDPV1 outbreak in Papua New Guinea: a cross-sectional study from 2020 to 2021Research in context
- Author
-
William Pomat, Rocio Lopez Cavestany, Visalakshi Jeyaseelan, Rebecca Ford, Janet Gare, Tigran Avagyan, Varja Grabovac, Deborah Bettels, Dessie Mekonnen, Kathryn Ann Vetter Jones, Bernardo Alfredo Mainou, and Ondrej Mach
- Subjects
Polio ,Vaccine-derived poliovirus ,Bivalent oral poliovirus vaccine ,Seroprevalence ,Outbreak response ,Papua New Guinea ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: In June 2018, a type 1 circulating vaccine-derived poliovirus (cVDPV1) outbreak was declared in Papua New Guinea (PNG), resulting in a total of 26 paralytic confirmed cases. Eight vaccination campaign rounds with bivalent oral poliovirus vaccine (bOPV) were carried out in response. Prevalence of neutralizing polio antibodies in children was assessed two years after the outbreak response was completed. Methods: We conducted a cross-sectional serological survey among children aged 6 months–10 years selected from six provinces in PNG to evaluate seroprevalence of neutralizing polio antibodies to the three poliovirus serotypes and analyse sociodemographic risk factors. Findings: We included 984 of 1006 enrolled children in the final analysis. The seroprevalence of neutralizing polio antibodies for serotype 1, 2 and 3 was 98.3% (95% CI: 97.4–98.9), 63.1% (95% CI: 60.1–66.1) and 95.0% (95% CI: 93.6–96.3), respectively. Children
- Published
- 2024
- Full Text
- View/download PDF